A Phase 1, Dose-Escalation/ Dose-Expansion Study Evaluating the Safety, pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvuluman (DURVA) and Daratumumab (DARA (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Protocol Number
639359MDS3001

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (FLAURA1)

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5160C00007

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
AV001

To Learn More Call
201-510-0910

An Open-label Bosutinib Treatment Extension Study for Subjects with Chronic Myeloid Leukemia (CML) who have Previously Participated in Bostutinib Studies B1871006 or B1871008

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
B1871040-1134

To Learn More Call
201-510-0910

A Phase 1, Dose-Escalation/ Dose-Expansion Study Evaluating the Safety, pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvuluman (DURVA) and Daratumumab (DARA (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Protocol Number
639359MDS3001

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (FLAURA1)

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5160C00007

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
AV001

To Learn More Call
201-510-0910

An Open-label Bosutinib Treatment Extension Study for Subjects with Chronic Myeloid Leukemia (CML) who have Previously Participated in Bostutinib Studies B1871006 or B1871008

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
B1871040-1134

To Learn More Call
201-510-0910

A Phase 1, Dose-Escalation/ Dose-Expansion Study Evaluating the Safety, pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvuluman (DURVA) and Daratumumab (DARA (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Protocol Number
639359MDS3001

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (FLAURA1)

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5160C00007

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
AV001

To Learn More Call
201-510-0910

An Open-label Bosutinib Treatment Extension Study for Subjects with Chronic Myeloid Leukemia (CML) who have Previously Participated in Bostutinib Studies B1871006 or B1871008

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
B1871040-1134

To Learn More Call
201-510-0910

A Phase 1, Dose-Escalation/ Dose-Expansion Study Evaluating the Safety, pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvuluman (DURVA) and Daratumumab (DARA (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Protocol Number
639359MDS3001

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (FLAURA1)

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5160C00007

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
AV001

To Learn More Call
201-510-0910

An Open-label Bosutinib Treatment Extension Study for Subjects with Chronic Myeloid Leukemia (CML) who have Previously Participated in Bostutinib Studies B1871006 or B1871008

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
B1871040-1134

To Learn More Call
201-510-0910

A Phase 1, Dose-Escalation/ Dose-Expansion Study Evaluating the Safety, pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvuluman (DURVA) and Daratumumab (DARA (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Protocol Number
639359MDS3001

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (FLAURA1)

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5160C00007

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
AV001

To Learn More Call
201-510-0910

An Open-label Bosutinib Treatment Extension Study for Subjects with Chronic Myeloid Leukemia (CML) who have Previously Participated in Bostutinib Studies B1871006 or B1871008

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
B1871040-1134

To Learn More Call
201-510-0910

A Phase 1, Dose-Escalation/ Dose-Expansion Study Evaluating the Safety, pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvuluman (DURVA) and Daratumumab (DARA (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Protocol Number
639359MDS3001

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (FLAURA1)

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5160C00007

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
AV001

To Learn More Call
201-510-0910

An Open-label Bosutinib Treatment Extension Study for Subjects with Chronic Myeloid Leukemia (CML) who have Previously Participated in Bostutinib Studies B1871006 or B1871008

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
B1871040-1134

To Learn More Call
201-510-0910

A Phase 1, Dose-Escalation/ Dose-Expansion Study Evaluating the Safety, pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvuluman (DURVA) and Daratumumab (DARA (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Protocol Number
639359MDS3001

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (FLAURA1)

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5160C00007

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
AV001

To Learn More Call
201-510-0910

An Open-label Bosutinib Treatment Extension Study for Subjects with Chronic Myeloid Leukemia (CML) who have Previously Participated in Bostutinib Studies B1871006 or B1871008

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
B1871040-1134

To Learn More Call
201-510-0910

A Phase 1, Dose-Escalation/ Dose-Expansion Study Evaluating the Safety, pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvuluman (DURVA) and Daratumumab (DARA (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Protocol Number
639359MDS3001

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (FLAURA1)

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5160C00007

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
AV001

To Learn More Call
201-510-0910

An Open-label Bosutinib Treatment Extension Study for Subjects with Chronic Myeloid Leukemia (CML) who have Previously Participated in Bostutinib Studies B1871006 or B1871008

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
B1871040-1134

To Learn More Call
201-510-0910

A Phase 1, Dose-Escalation/ Dose-Expansion Study Evaluating the Safety, pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvuluman (DURVA) and Daratumumab (DARA (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Protocol Number
639359MDS3001

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (FLAURA1)

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5160C00007

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
AV001

To Learn More Call
201-510-0910

An Open-label Bosutinib Treatment Extension Study for Subjects with Chronic Myeloid Leukemia (CML) who have Previously Participated in Bostutinib Studies B1871006 or B1871008

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
B1871040-1134

To Learn More Call
201-510-0910

A Phase 1, Dose-Escalation/ Dose-Expansion Study Evaluating the Safety, pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvuluman (DURVA) and Daratumumab (DARA (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Protocol Number
639359MDS3001

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (FLAURA1)

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5160C00007

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
AV001

To Learn More Call
201-510-0910

An Open-label Bosutinib Treatment Extension Study for Subjects with Chronic Myeloid Leukemia (CML) who have Previously Participated in Bostutinib Studies B1871006 or B1871008

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
B1871040-1134

To Learn More Call
201-510-0910

A Phase 1, Dose-Escalation/ Dose-Expansion Study Evaluating the Safety, pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvuluman (DURVA) and Daratumumab (DARA (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Protocol Number
639359MDS3001

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (FLAURA1)

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5160C00007

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
AV001

To Learn More Call
201-510-0910

An Open-label Bosutinib Treatment Extension Study for Subjects with Chronic Myeloid Leukemia (CML) who have Previously Participated in Bostutinib Studies B1871006 or B1871008

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
B1871040-1134

To Learn More Call
201-510-0910

A Phase 1, Dose-Escalation/ Dose-Expansion Study Evaluating the Safety, pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvuluman (DURVA) and Daratumumab (DARA (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Protocol Number
639359MDS3001

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (FLAURA1)

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5160C00007

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
AV001

To Learn More Call
201-510-0910

An Open-label Bosutinib Treatment Extension Study for Subjects with Chronic Myeloid Leukemia (CML) who have Previously Participated in Bostutinib Studies B1871006 or B1871008

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
B1871040-1134

To Learn More Call
201-510-0910

A Phase 1, Dose-Escalation/ Dose-Expansion Study Evaluating the Safety, pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvuluman (DURVA) and Daratumumab (DARA (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Protocol Number
639359MDS3001

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (FLAURA1)

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5160C00007

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
AV001

To Learn More Call
201-510-0910

An Open-label Bosutinib Treatment Extension Study for Subjects with Chronic Myeloid Leukemia (CML) who have Previously Participated in Bostutinib Studies B1871006 or B1871008

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
B1871040-1134

To Learn More Call
201-510-0910

A Phase 1, Dose-Escalation/ Dose-Expansion Study Evaluating the Safety, pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvuluman (DURVA) and Daratumumab (DARA (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Protocol Number
639359MDS3001

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (FLAURA1)

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5160C00007

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
AV001

To Learn More Call
201-510-0910

An Open-label Bosutinib Treatment Extension Study for Subjects with Chronic Myeloid Leukemia (CML) who have Previously Participated in Bostutinib Studies B1871006 or B1871008

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
B1871040-1134

To Learn More Call
201-510-0910

A Phase 1, Dose-Escalation/ Dose-Expansion Study Evaluating the Safety, pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvuluman (DURVA) and Daratumumab (DARA (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Protocol Number
639359MDS3001

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (FLAURA1)

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5160C00007

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
AV001

To Learn More Call
201-510-0910

An Open-label Bosutinib Treatment Extension Study for Subjects with Chronic Myeloid Leukemia (CML) who have Previously Participated in Bostutinib Studies B1871006 or B1871008

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
B1871040-1134

To Learn More Call
201-510-0910

A Phase 1, Dose-Escalation/ Dose-Expansion Study Evaluating the Safety, pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvuluman (DURVA) and Daratumumab (DARA (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Protocol Number
639359MDS3001

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (FLAURA1)

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5160C00007

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
AV001

To Learn More Call
201-510-0910

An Open-label Bosutinib Treatment Extension Study for Subjects with Chronic Myeloid Leukemia (CML) who have Previously Participated in Bostutinib Studies B1871006 or B1871008

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
B1871040-1134

To Learn More Call
201-510-0910

A Phase 1, Dose-Escalation/ Dose-Expansion Study Evaluating the Safety, pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvuluman (DURVA) and Daratumumab (DARA (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Protocol Number
639359MDS3001

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (FLAURA1)

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5160C00007

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
AV001

To Learn More Call
201-510-0910

An Open-label Bosutinib Treatment Extension Study for Subjects with Chronic Myeloid Leukemia (CML) who have Previously Participated in Bostutinib Studies B1871006 or B1871008

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
B1871040-1134

To Learn More Call
201-510-0910

A Phase 1, Dose-Escalation/ Dose-Expansion Study Evaluating the Safety, pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvuluman (DURVA) and Daratumumab (DARA (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Protocol Number
639359MDS3001

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (FLAURA1)

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5160C00007

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
AV001

To Learn More Call
201-510-0910

An Open-label Bosutinib Treatment Extension Study for Subjects with Chronic Myeloid Leukemia (CML) who have Previously Participated in Bostutinib Studies B1871006 or B1871008

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
B1871040-1134

To Learn More Call
201-510-0910

A Phase 1, Dose-Escalation/ Dose-Expansion Study Evaluating the Safety, pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvuluman (DURVA) and Daratumumab (DARA (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Protocol Number
639359MDS3001

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (FLAURA1)

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5160C00007

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
AV001

To Learn More Call
201-510-0910

An Open-label Bosutinib Treatment Extension Study for Subjects with Chronic Myeloid Leukemia (CML) who have Previously Participated in Bostutinib Studies B1871006 or B1871008

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
B1871040-1134

To Learn More Call
201-510-0910

A Phase 1, Dose-Escalation/ Dose-Expansion Study Evaluating the Safety, pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvuluman (DURVA) and Daratumumab (DARA (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Protocol Number
639359MDS3001

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (FLAURA1)

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5160C00007

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
AV001

To Learn More Call
201-510-0910

An Open-label Bosutinib Treatment Extension Study for Subjects with Chronic Myeloid Leukemia (CML) who have Previously Participated in Bostutinib Studies B1871006 or B1871008

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
B1871040-1134

To Learn More Call
201-510-0910

A Phase 1, Dose-Escalation/ Dose-Expansion Study Evaluating the Safety, pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvuluman (DURVA) and Daratumumab (DARA (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Protocol Number
639359MDS3001

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (FLAURA1)

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5160C00007

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
AV001

To Learn More Call
201-510-0910

An Open-label Bosutinib Treatment Extension Study for Subjects with Chronic Myeloid Leukemia (CML) who have Previously Participated in Bostutinib Studies B1871006 or B1871008

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
B1871040-1134

To Learn More Call
201-510-0910

A Phase 1, Dose-Escalation/ Dose-Expansion Study Evaluating the Safety, pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvuluman (DURVA) and Daratumumab (DARA (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Protocol Number
639359MDS3001

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (FLAURA1)

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5160C00007

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
AV001

To Learn More Call
201-510-0910

An Open-label Bosutinib Treatment Extension Study for Subjects with Chronic Myeloid Leukemia (CML) who have Previously Participated in Bostutinib Studies B1871006 or B1871008

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
B1871040-1134

To Learn More Call
201-510-0910

A Phase 1, Dose-Escalation/ Dose-Expansion Study Evaluating the Safety, pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvuluman (DURVA) and Daratumumab (DARA (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Protocol Number
639359MDS3001

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (FLAURA1)

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5160C00007

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
AV001

To Learn More Call
201-510-0910

An Open-label Bosutinib Treatment Extension Study for Subjects with Chronic Myeloid Leukemia (CML) who have Previously Participated in Bostutinib Studies B1871006 or B1871008

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
B1871040-1134

To Learn More Call
201-510-0910

A Phase 1, Dose-Escalation/ Dose-Expansion Study Evaluating the Safety, pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvuluman (DURVA) and Daratumumab (DARA (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Protocol Number
639359MDS3001

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (FLAURA1)

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5160C00007

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
AV001

To Learn More Call
201-510-0910

An Open-label Bosutinib Treatment Extension Study for Subjects with Chronic Myeloid Leukemia (CML) who have Previously Participated in Bostutinib Studies B1871006 or B1871008

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
B1871040-1134

To Learn More Call
201-510-0910

A Phase 1, Dose-Escalation/ Dose-Expansion Study Evaluating the Safety, pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvuluman (DURVA) and Daratumumab (DARA (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Protocol Number
639359MDS3001

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (FLAURA1)

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5160C00007

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
AV001

To Learn More Call
201-510-0910

An Open-label Bosutinib Treatment Extension Study for Subjects with Chronic Myeloid Leukemia (CML) who have Previously Participated in Bostutinib Studies B1871006 or B1871008

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
B1871040-1134

To Learn More Call
201-510-0910

A Phase 1, Dose-Escalation/ Dose-Expansion Study Evaluating the Safety, pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvuluman (DURVA) and Daratumumab (DARA (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Protocol Number
639359MDS3001

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (FLAURA1)

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5160C00007

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
AV001

To Learn More Call
201-510-0910

An Open-label Bosutinib Treatment Extension Study for Subjects with Chronic Myeloid Leukemia (CML) who have Previously Participated in Bostutinib Studies B1871006 or B1871008

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
B1871040-1134

To Learn More Call
201-510-0910

A Phase 1, Dose-Escalation/ Dose-Expansion Study Evaluating the Safety, pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvuluman (DURVA) and Daratumumab (DARA (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Protocol Number
639359MDS3001

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (FLAURA1)

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5160C00007

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
AV001

To Learn More Call
201-510-0910

An Open-label Bosutinib Treatment Extension Study for Subjects with Chronic Myeloid Leukemia (CML) who have Previously Participated in Bostutinib Studies B1871006 or B1871008

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
B1871040-1134

To Learn More Call
201-510-0910

A Phase 1, Dose-Escalation/ Dose-Expansion Study Evaluating the Safety, pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvuluman (DURVA) and Daratumumab (DARA (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Protocol Number
639359MDS3001

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (FLAURA1)

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5160C00007

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
AV001

To Learn More Call
201-510-0910

An Open-label Bosutinib Treatment Extension Study for Subjects with Chronic Myeloid Leukemia (CML) who have Previously Participated in Bostutinib Studies B1871006 or B1871008

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
B1871040-1134

To Learn More Call
201-510-0910

A Phase 1, Dose-Escalation/ Dose-Expansion Study Evaluating the Safety, pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvuluman (DURVA) and Daratumumab (DARA (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Protocol Number
639359MDS3001

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (FLAURA1)

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5160C00007

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
AV001

To Learn More Call
201-510-0910

An Open-label Bosutinib Treatment Extension Study for Subjects with Chronic Myeloid Leukemia (CML) who have Previously Participated in Bostutinib Studies B1871006 or B1871008

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
B1871040-1134

To Learn More Call
201-510-0910

A Phase 1, Dose-Escalation/ Dose-Expansion Study Evaluating the Safety, pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvuluman (DURVA) and Daratumumab (DARA (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Protocol Number
639359MDS3001

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (FLAURA1)

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5160C00007

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
AV001

To Learn More Call
201-510-0910

An Open-label Bosutinib Treatment Extension Study for Subjects with Chronic Myeloid Leukemia (CML) who have Previously Participated in Bostutinib Studies B1871006 or B1871008

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
B1871040-1134

To Learn More Call
201-510-0910

A Phase 1, Dose-Escalation/ Dose-Expansion Study Evaluating the Safety, pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvuluman (DURVA) and Daratumumab (DARA (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Protocol Number
639359MDS3001

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (FLAURA1)

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5160C00007

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
AV001

To Learn More Call
201-510-0910

An Open-label Bosutinib Treatment Extension Study for Subjects with Chronic Myeloid Leukemia (CML) who have Previously Participated in Bostutinib Studies B1871006 or B1871008

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
B1871040-1134

To Learn More Call
201-510-0910

A Phase 1, Dose-Escalation/ Dose-Expansion Study Evaluating the Safety, pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvuluman (DURVA) and Daratumumab (DARA (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Protocol Number
639359MDS3001

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (FLAURA1)

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5160C00007

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
AV001

To Learn More Call
201-510-0910

An Open-label Bosutinib Treatment Extension Study for Subjects with Chronic Myeloid Leukemia (CML) who have Previously Participated in Bostutinib Studies B1871006 or B1871008

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
B1871040-1134

To Learn More Call
201-510-0910

A Phase 1, Dose-Escalation/ Dose-Expansion Study Evaluating the Safety, pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvuluman (DURVA) and Daratumumab (DARA (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Protocol Number
639359MDS3001

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (FLAURA1)

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5160C00007

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
AV001

To Learn More Call
201-510-0910

An Open-label Bosutinib Treatment Extension Study for Subjects with Chronic Myeloid Leukemia (CML) who have Previously Participated in Bostutinib Studies B1871006 or B1871008

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
B1871040-1134

To Learn More Call
201-510-0910

A Phase 1, Dose-Escalation/ Dose-Expansion Study Evaluating the Safety, pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvuluman (DURVA) and Daratumumab (DARA (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Protocol Number
639359MDS3001

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (FLAURA1)

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5160C00007

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
AV001

To Learn More Call
201-510-0910

An Open-label Bosutinib Treatment Extension Study for Subjects with Chronic Myeloid Leukemia (CML) who have Previously Participated in Bostutinib Studies B1871006 or B1871008

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
B1871040-1134

To Learn More Call
201-510-0910

A Phase 1, Dose-Escalation/ Dose-Expansion Study Evaluating the Safety, pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvuluman (DURVA) and Daratumumab (DARA (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Protocol Number
639359MDS3001

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (FLAURA1)

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5160C00007

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
AV001

To Learn More Call
201-510-0910

An Open-label Bosutinib Treatment Extension Study for Subjects with Chronic Myeloid Leukemia (CML) who have Previously Participated in Bostutinib Studies B1871006 or B1871008

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
B1871040-1134

To Learn More Call
201-510-0910

A Phase 1, Dose-Escalation/ Dose-Expansion Study Evaluating the Safety, pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvuluman (DURVA) and Daratumumab (DARA (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Protocol Number
639359MDS3001

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (FLAURA1)

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5160C00007

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
AV001

To Learn More Call
201-510-0910

An Open-label Bosutinib Treatment Extension Study for Subjects with Chronic Myeloid Leukemia (CML) who have Previously Participated in Bostutinib Studies B1871006 or B1871008

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
B1871040-1134

To Learn More Call
201-510-0910

A Phase 1, Dose-Escalation/ Dose-Expansion Study Evaluating the Safety, pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvuluman (DURVA) and Daratumumab (DARA (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Protocol Number
639359MDS3001

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (FLAURA1)

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5160C00007

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
AV001

To Learn More Call
201-510-0910

An Open-label Bosutinib Treatment Extension Study for Subjects with Chronic Myeloid Leukemia (CML) who have Previously Participated in Bostutinib Studies B1871006 or B1871008

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
B1871040-1134

To Learn More Call
201-510-0910

A Phase 1, Dose-Escalation/ Dose-Expansion Study Evaluating the Safety, pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvuluman (DURVA) and Daratumumab (DARA (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Protocol Number
639359MDS3001

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (FLAURA1)

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5160C00007

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
AV001

To Learn More Call
201-510-0910

An Open-label Bosutinib Treatment Extension Study for Subjects with Chronic Myeloid Leukemia (CML) who have Previously Participated in Bostutinib Studies B1871006 or B1871008

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
B1871040-1134

To Learn More Call
201-510-0910

A Phase 1, Dose-Escalation/ Dose-Expansion Study Evaluating the Safety, pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvuluman (DURVA) and Daratumumab (DARA (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Protocol Number
639359MDS3001

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (FLAURA1)

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5160C00007

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
AV001

To Learn More Call
201-510-0910

An Open-label Bosutinib Treatment Extension Study for Subjects with Chronic Myeloid Leukemia (CML) who have Previously Participated in Bostutinib Studies B1871006 or B1871008

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
B1871040-1134

To Learn More Call
201-510-0910

A Phase 1, Dose-Escalation/ Dose-Expansion Study Evaluating the Safety, pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvuluman (DURVA) and Daratumumab (DARA (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Protocol Number
639359MDS3001

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (FLAURA1)

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5160C00007

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
AV001

To Learn More Call
201-510-0910

An Open-label Bosutinib Treatment Extension Study for Subjects with Chronic Myeloid Leukemia (CML) who have Previously Participated in Bostutinib Studies B1871006 or B1871008

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
B1871040-1134

To Learn More Call
201-510-0910

A Phase 1, Dose-Escalation/ Dose-Expansion Study Evaluating the Safety, pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvuluman (DURVA) and Daratumumab (DARA (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Protocol Number
639359MDS3001

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (FLAURA1)

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5160C00007

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
AV001

To Learn More Call
201-510-0910

An Open-label Bosutinib Treatment Extension Study for Subjects with Chronic Myeloid Leukemia (CML) who have Previously Participated in Bostutinib Studies B1871006 or B1871008

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
B1871040-1134

To Learn More Call
201-510-0910

A Phase 1, Dose-Escalation/ Dose-Expansion Study Evaluating the Safety, pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvuluman (DURVA) and Daratumumab (DARA (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Protocol Number
639359MDS3001

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (FLAURA1)

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5160C00007

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
AV001

To Learn More Call
201-510-0910

An Open-label Bosutinib Treatment Extension Study for Subjects with Chronic Myeloid Leukemia (CML) who have Previously Participated in Bostutinib Studies B1871006 or B1871008

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
B1871040-1134

To Learn More Call
201-510-0910

A Phase 1, Dose-Escalation/ Dose-Expansion Study Evaluating the Safety, pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvuluman (DURVA) and Daratumumab (DARA (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Protocol Number
639359MDS3001

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (FLAURA1)

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5160C00007

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
AV001

To Learn More Call
201-510-0910

An Open-label Bosutinib Treatment Extension Study for Subjects with Chronic Myeloid Leukemia (CML) who have Previously Participated in Bostutinib Studies B1871006 or B1871008

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
B1871040-1134

To Learn More Call
201-510-0910

A Phase 1, Dose-Escalation/ Dose-Expansion Study Evaluating the Safety, pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvuluman (DURVA) and Daratumumab (DARA (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Protocol Number
639359MDS3001

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (FLAURA1)

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5160C00007

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
AV001

To Learn More Call
201-510-0910

An Open-label Bosutinib Treatment Extension Study for Subjects with Chronic Myeloid Leukemia (CML) who have Previously Participated in Bostutinib Studies B1871006 or B1871008

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
B1871040-1134

To Learn More Call
201-510-0910

A Phase 1, Dose-Escalation/ Dose-Expansion Study Evaluating the Safety, pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvuluman (DURVA) and Daratumumab (DARA (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Protocol Number
639359MDS3001

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (FLAURA1)

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5160C00007

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
AV001

To Learn More Call
201-510-0910

An Open-label Bosutinib Treatment Extension Study for Subjects with Chronic Myeloid Leukemia (CML) who have Previously Participated in Bostutinib Studies B1871006 or B1871008

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
B1871040-1134

To Learn More Call
201-510-0910

A Phase 1, Dose-Escalation/ Dose-Expansion Study Evaluating the Safety, pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvuluman (DURVA) and Daratumumab (DARA (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Protocol Number
639359MDS3001

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (FLAURA1)

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5160C00007

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
AV001

To Learn More Call
201-510-0910

An Open-label Bosutinib Treatment Extension Study for Subjects with Chronic Myeloid Leukemia (CML) who have Previously Participated in Bostutinib Studies B1871006 or B1871008

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
B1871040-1134

To Learn More Call
201-510-0910

A Phase 1, Dose-Escalation/ Dose-Expansion Study Evaluating the Safety, pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvuluman (DURVA) and Daratumumab (DARA (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Protocol Number
639359MDS3001

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (FLAURA1)

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5160C00007

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
AV001

To Learn More Call
201-510-0910

An Open-label Bosutinib Treatment Extension Study for Subjects with Chronic Myeloid Leukemia (CML) who have Previously Participated in Bostutinib Studies B1871006 or B1871008

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
B1871040-1134

To Learn More Call
201-510-0910

A Phase 1, Dose-Escalation/ Dose-Expansion Study Evaluating the Safety, pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvuluman (DURVA) and Daratumumab (DARA (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Protocol Number
639359MDS3001

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (FLAURA1)

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5160C00007

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
AV001

To Learn More Call
201-510-0910

An Open-label Bosutinib Treatment Extension Study for Subjects with Chronic Myeloid Leukemia (CML) who have Previously Participated in Bostutinib Studies B1871006 or B1871008

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
B1871040-1134

To Learn More Call
201-510-0910

A Phase 1, Dose-Escalation/ Dose-Expansion Study Evaluating the Safety, pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvuluman (DURVA) and Daratumumab (DARA (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Protocol Number
639359MDS3001

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (FLAURA1)

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5160C00007

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
AV001

To Learn More Call
201-510-0910

An Open-label Bosutinib Treatment Extension Study for Subjects with Chronic Myeloid Leukemia (CML) who have Previously Participated in Bostutinib Studies B1871006 or B1871008

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
B1871040-1134

To Learn More Call
201-510-0910

A Phase 1, Dose-Escalation/ Dose-Expansion Study Evaluating the Safety, pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvuluman (DURVA) and Daratumumab (DARA (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Protocol Number
639359MDS3001

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (FLAURA1)

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5160C00007

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
AV001

To Learn More Call
201-510-0910

An Open-label Bosutinib Treatment Extension Study for Subjects with Chronic Myeloid Leukemia (CML) who have Previously Participated in Bostutinib Studies B1871006 or B1871008

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
B1871040-1134

To Learn More Call
201-510-0910

A Phase 1, Dose-Escalation/ Dose-Expansion Study Evaluating the Safety, pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvuluman (DURVA) and Daratumumab (DARA (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Protocol Number
639359MDS3001

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (FLAURA1)

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5160C00007

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
AV001

To Learn More Call
201-510-0910

An Open-label Bosutinib Treatment Extension Study for Subjects with Chronic Myeloid Leukemia (CML) who have Previously Participated in Bostutinib Studies B1871006 or B1871008

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
B1871040-1134

To Learn More Call
201-510-0910

A Phase 1, Dose-Escalation/ Dose-Expansion Study Evaluating the Safety, pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvuluman (DURVA) and Daratumumab (DARA (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Protocol Number
639359MDS3001

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (FLAURA1)

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5160C00007

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
AV001

To Learn More Call
201-510-0910

An Open-label Bosutinib Treatment Extension Study for Subjects with Chronic Myeloid Leukemia (CML) who have Previously Participated in Bostutinib Studies B1871006 or B1871008

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
B1871040-1134

To Learn More Call
201-510-0910

A Phase 1, Dose-Escalation/ Dose-Expansion Study Evaluating the Safety, pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvuluman (DURVA) and Daratumumab (DARA (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Protocol Number
639359MDS3001

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (FLAURA1)

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5160C00007

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
AV001

To Learn More Call
201-510-0910

An Open-label Bosutinib Treatment Extension Study for Subjects with Chronic Myeloid Leukemia (CML) who have Previously Participated in Bostutinib Studies B1871006 or B1871008

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
B1871040-1134

To Learn More Call
201-510-0910

A Phase 1, Dose-Escalation/ Dose-Expansion Study Evaluating the Safety, pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvuluman (DURVA) and Daratumumab (DARA (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Protocol Number
639359MDS3001

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (FLAURA1)

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5160C00007

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
AV001

To Learn More Call
201-510-0910

An Open-label Bosutinib Treatment Extension Study for Subjects with Chronic Myeloid Leukemia (CML) who have Previously Participated in Bostutinib Studies B1871006 or B1871008

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
B1871040-1134

To Learn More Call
201-510-0910

A Phase 1, Dose-Escalation/ Dose-Expansion Study Evaluating the Safety, pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvuluman (DURVA) and Daratumumab (DARA (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Protocol Number
639359MDS3001

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (FLAURA1)

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5160C00007

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
AV001

To Learn More Call
201-510-0910

An Open-label Bosutinib Treatment Extension Study for Subjects with Chronic Myeloid Leukemia (CML) who have Previously Participated in Bostutinib Studies B1871006 or B1871008

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
B1871040-1134

To Learn More Call
201-510-0910

A Phase 1, Dose-Escalation/ Dose-Expansion Study Evaluating the Safety, pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvuluman (DURVA) and Daratumumab (DARA (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Protocol Number
639359MDS3001

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (FLAURA1)

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5160C00007

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
AV001

To Learn More Call
201-510-0910

An Open-label Bosutinib Treatment Extension Study for Subjects with Chronic Myeloid Leukemia (CML) who have Previously Participated in Bostutinib Studies B1871006 or B1871008

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
B1871040-1134

To Learn More Call
201-510-0910

A Phase 1, Dose-Escalation/ Dose-Expansion Study Evaluating the Safety, pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvuluman (DURVA) and Daratumumab (DARA (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Protocol Number
639359MDS3001

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (FLAURA1)

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5160C00007

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
AV001

To Learn More Call
201-510-0910

An Open-label Bosutinib Treatment Extension Study for Subjects with Chronic Myeloid Leukemia (CML) who have Previously Participated in Bostutinib Studies B1871006 or B1871008

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
B1871040-1134

To Learn More Call
201-510-0910

A Phase 1, Dose-Escalation/ Dose-Expansion Study Evaluating the Safety, pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvuluman (DURVA) and Daratumumab (DARA (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Protocol Number
639359MDS3001

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (FLAURA1)

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5160C00007

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
AV001

To Learn More Call
201-510-0910

An Open-label Bosutinib Treatment Extension Study for Subjects with Chronic Myeloid Leukemia (CML) who have Previously Participated in Bostutinib Studies B1871006 or B1871008

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
B1871040-1134

To Learn More Call
201-510-0910

A Phase 1, Dose-Escalation/ Dose-Expansion Study Evaluating the Safety, pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvuluman (DURVA) and Daratumumab (DARA (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Protocol Number
639359MDS3001

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (FLAURA1)

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5160C00007

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
AV001

To Learn More Call
201-510-0910

An Open-label Bosutinib Treatment Extension Study for Subjects with Chronic Myeloid Leukemia (CML) who have Previously Participated in Bostutinib Studies B1871006 or B1871008

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
B1871040-1134

To Learn More Call
201-510-0910

A Phase 1, Dose-Escalation/ Dose-Expansion Study Evaluating the Safety, pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvuluman (DURVA) and Daratumumab (DARA (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Protocol Number
639359MDS3001

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (FLAURA1)

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5160C00007

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
AV001

To Learn More Call
201-510-0910

An Open-label Bosutinib Treatment Extension Study for Subjects with Chronic Myeloid Leukemia (CML) who have Previously Participated in Bostutinib Studies B1871006 or B1871008

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
B1871040-1134

To Learn More Call
201-510-0910

A Phase 1, Dose-Escalation/ Dose-Expansion Study Evaluating the Safety, pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvuluman (DURVA) and Daratumumab (DARA (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Protocol Number
639359MDS3001

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (FLAURA1)

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5160C00007

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
AV001

To Learn More Call
201-510-0910

An Open-label Bosutinib Treatment Extension Study for Subjects with Chronic Myeloid Leukemia (CML) who have Previously Participated in Bostutinib Studies B1871006 or B1871008

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
B1871040-1134

To Learn More Call
201-510-0910

A Phase 1, Dose-Escalation/ Dose-Expansion Study Evaluating the Safety, pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvuluman (DURVA) and Daratumumab (DARA (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Protocol Number
639359MDS3001

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (FLAURA1)

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5160C00007

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
AV001

To Learn More Call
201-510-0910

An Open-label Bosutinib Treatment Extension Study for Subjects with Chronic Myeloid Leukemia (CML) who have Previously Participated in Bostutinib Studies B1871006 or B1871008

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
B1871040-1134

To Learn More Call
201-510-0910

A Phase 1, Dose-Escalation/ Dose-Expansion Study Evaluating the Safety, pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvuluman (DURVA) and Daratumumab (DARA (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Protocol Number
639359MDS3001

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (FLAURA1)

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5160C00007

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
AV001

To Learn More Call
201-510-0910

An Open-label Bosutinib Treatment Extension Study for Subjects with Chronic Myeloid Leukemia (CML) who have Previously Participated in Bostutinib Studies B1871006 or B1871008

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
B1871040-1134

To Learn More Call
201-510-0910

A Phase 1, Dose-Escalation/ Dose-Expansion Study Evaluating the Safety, pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvuluman (DURVA) and Daratumumab (DARA (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Protocol Number
639359MDS3001

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (FLAURA1)

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5160C00007

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
AV001

To Learn More Call
201-510-0910

An Open-label Bosutinib Treatment Extension Study for Subjects with Chronic Myeloid Leukemia (CML) who have Previously Participated in Bostutinib Studies B1871006 or B1871008

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
B1871040-1134

To Learn More Call
201-510-0910

A Phase 1, Dose-Escalation/ Dose-Expansion Study Evaluating the Safety, pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvuluman (DURVA) and Daratumumab (DARA (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Protocol Number
639359MDS3001

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (FLAURA1)

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5160C00007

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
AV001

To Learn More Call
201-510-0910

An Open-label Bosutinib Treatment Extension Study for Subjects with Chronic Myeloid Leukemia (CML) who have Previously Participated in Bostutinib Studies B1871006 or B1871008

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
B1871040-1134

To Learn More Call
201-510-0910

A Phase 1, Dose-Escalation/ Dose-Expansion Study Evaluating the Safety, pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvuluman (DURVA) and Daratumumab (DARA (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Protocol Number
639359MDS3001

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (FLAURA1)

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5160C00007

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
AV001

To Learn More Call
201-510-0910

An Open-label Bosutinib Treatment Extension Study for Subjects with Chronic Myeloid Leukemia (CML) who have Previously Participated in Bostutinib Studies B1871006 or B1871008

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
B1871040-1134

To Learn More Call
201-510-0910

A Phase 1, Dose-Escalation/ Dose-Expansion Study Evaluating the Safety, pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvuluman (DURVA) and Daratumumab (DARA (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Protocol Number
639359MDS3001

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (FLAURA1)

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5160C00007

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
AV001

To Learn More Call
201-510-0910

An Open-label Bosutinib Treatment Extension Study for Subjects with Chronic Myeloid Leukemia (CML) who have Previously Participated in Bostutinib Studies B1871006 or B1871008

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
B1871040-1134

To Learn More Call
201-510-0910

A Phase 1, Dose-Escalation/ Dose-Expansion Study Evaluating the Safety, pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvuluman (DURVA) and Daratumumab (DARA (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Protocol Number
639359MDS3001

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (FLAURA1)

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5160C00007

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
AV001

To Learn More Call
201-510-0910

An Open-label Bosutinib Treatment Extension Study for Subjects with Chronic Myeloid Leukemia (CML) who have Previously Participated in Bostutinib Studies B1871006 or B1871008

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
B1871040-1134

To Learn More Call
201-510-0910

A Phase 1, Dose-Escalation/ Dose-Expansion Study Evaluating the Safety, pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvuluman (DURVA) and Daratumumab (DARA (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Protocol Number
639359MDS3001

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (FLAURA1)

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5160C00007

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
AV001

To Learn More Call
201-510-0910

An Open-label Bosutinib Treatment Extension Study for Subjects with Chronic Myeloid Leukemia (CML) who have Previously Participated in Bostutinib Studies B1871006 or B1871008

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
B1871040-1134

To Learn More Call
201-510-0910

A Phase 1, Dose-Escalation/ Dose-Expansion Study Evaluating the Safety, pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvuluman (DURVA) and Daratumumab (DARA (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Protocol Number
639359MDS3001

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (FLAURA1)

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5160C00007

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
AV001

To Learn More Call
201-510-0910

An Open-label Bosutinib Treatment Extension Study for Subjects with Chronic Myeloid Leukemia (CML) who have Previously Participated in Bostutinib Studies B1871006 or B1871008

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
B1871040-1134

To Learn More Call
201-510-0910

A Phase 1, Dose-Escalation/ Dose-Expansion Study Evaluating the Safety, pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvuluman (DURVA) and Daratumumab (DARA (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Protocol Number
639359MDS3001

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (FLAURA1)

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5160C00007

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
AV001

To Learn More Call
201-510-0910

An Open-label Bosutinib Treatment Extension Study for Subjects with Chronic Myeloid Leukemia (CML) who have Previously Participated in Bostutinib Studies B1871006 or B1871008

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
B1871040-1134

To Learn More Call
201-510-0910

A Phase 1, Dose-Escalation/ Dose-Expansion Study Evaluating the Safety, pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvuluman (DURVA) and Daratumumab (DARA (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Protocol Number
639359MDS3001

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (FLAURA1)

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5160C00007

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
AV001

To Learn More Call
201-510-0910

An Open-label Bosutinib Treatment Extension Study for Subjects with Chronic Myeloid Leukemia (CML) who have Previously Participated in Bostutinib Studies B1871006 or B1871008

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
B1871040-1134

To Learn More Call
201-510-0910

A Phase 1, Dose-Escalation/ Dose-Expansion Study Evaluating the Safety, pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvuluman (DURVA) and Daratumumab (DARA (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Protocol Number
639359MDS3001

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (FLAURA1)

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5160C00007

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
AV001

To Learn More Call
201-510-0910

An Open-label Bosutinib Treatment Extension Study for Subjects with Chronic Myeloid Leukemia (CML) who have Previously Participated in Bostutinib Studies B1871006 or B1871008

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
B1871040-1134

To Learn More Call
201-510-0910

A Phase 1, Dose-Escalation/ Dose-Expansion Study Evaluating the Safety, pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvuluman (DURVA) and Daratumumab (DARA (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Protocol Number
639359MDS3001

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (FLAURA1)

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5160C00007

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
AV001

To Learn More Call
201-510-0910

An Open-label Bosutinib Treatment Extension Study for Subjects with Chronic Myeloid Leukemia (CML) who have Previously Participated in Bostutinib Studies B1871006 or B1871008

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
B1871040-1134

To Learn More Call
201-510-0910

A Phase 1, Dose-Escalation/ Dose-Expansion Study Evaluating the Safety, pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvuluman (DURVA) and Daratumumab (DARA (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Protocol Number
639359MDS3001

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (FLAURA1)

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5160C00007

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
AV001

To Learn More Call
201-510-0910

An Open-label Bosutinib Treatment Extension Study for Subjects with Chronic Myeloid Leukemia (CML) who have Previously Participated in Bostutinib Studies B1871006 or B1871008

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
B1871040-1134

To Learn More Call
201-510-0910

A Phase 1, Dose-Escalation/ Dose-Expansion Study Evaluating the Safety, pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvuluman (DURVA) and Daratumumab (DARA (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Protocol Number
639359MDS3001

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (FLAURA1)

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5160C00007

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
AV001

To Learn More Call
201-510-0910

An Open-label Bosutinib Treatment Extension Study for Subjects with Chronic Myeloid Leukemia (CML) who have Previously Participated in Bostutinib Studies B1871006 or B1871008

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
B1871040-1134

To Learn More Call
201-510-0910

A Phase 1, Dose-Escalation/ Dose-Expansion Study Evaluating the Safety, pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvuluman (DURVA) and Daratumumab (DARA (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Protocol Number
639359MDS3001

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (FLAURA1)

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5160C00007

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
AV001

To Learn More Call
201-510-0910

An Open-label Bosutinib Treatment Extension Study for Subjects with Chronic Myeloid Leukemia (CML) who have Previously Participated in Bostutinib Studies B1871006 or B1871008

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
B1871040-1134

To Learn More Call
201-510-0910

A Phase 1, Dose-Escalation/ Dose-Expansion Study Evaluating the Safety, pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvuluman (DURVA) and Daratumumab (DARA (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Protocol Number
639359MDS3001

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (FLAURA1)

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5160C00007

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
AV001

To Learn More Call
201-510-0910

An Open-label Bosutinib Treatment Extension Study for Subjects with Chronic Myeloid Leukemia (CML) who have Previously Participated in Bostutinib Studies B1871006 or B1871008

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
B1871040-1134

To Learn More Call
201-510-0910

A Phase 1, Dose-Escalation/ Dose-Expansion Study Evaluating the Safety, pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvuluman (DURVA) and Daratumumab (DARA (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Protocol Number
639359MDS3001

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (FLAURA1)

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5160C00007

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
AV001

To Learn More Call
201-510-0910

An Open-label Bosutinib Treatment Extension Study for Subjects with Chronic Myeloid Leukemia (CML) who have Previously Participated in Bostutinib Studies B1871006 or B1871008

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
B1871040-1134

To Learn More Call
201-510-0910

A Phase 1, Dose-Escalation/ Dose-Expansion Study Evaluating the Safety, pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvuluman (DURVA) and Daratumumab (DARA (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Protocol Number
639359MDS3001

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (FLAURA1)

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5160C00007

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
AV001

To Learn More Call
201-510-0910

An Open-label Bosutinib Treatment Extension Study for Subjects with Chronic Myeloid Leukemia (CML) who have Previously Participated in Bostutinib Studies B1871006 or B1871008

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
B1871040-1134

To Learn More Call
201-510-0910

A Phase 1, Dose-Escalation/ Dose-Expansion Study Evaluating the Safety, pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvuluman (DURVA) and Daratumumab (DARA (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Protocol Number
639359MDS3001

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (FLAURA1)

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5160C00007

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
AV001

To Learn More Call
201-510-0910

An Open-label Bosutinib Treatment Extension Study for Subjects with Chronic Myeloid Leukemia (CML) who have Previously Participated in Bostutinib Studies B1871006 or B1871008

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
B1871040-1134

To Learn More Call
201-510-0910

A Phase 1, Dose-Escalation/ Dose-Expansion Study Evaluating the Safety, pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvuluman (DURVA) and Daratumumab (DARA (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Protocol Number
639359MDS3001

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (FLAURA1)

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5160C00007

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
AV001

To Learn More Call
201-510-0910

An Open-label Bosutinib Treatment Extension Study for Subjects with Chronic Myeloid Leukemia (CML) who have Previously Participated in Bostutinib Studies B1871006 or B1871008

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
B1871040-1134

To Learn More Call
201-510-0910

A Phase 1, Dose-Escalation/ Dose-Expansion Study Evaluating the Safety, pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvuluman (DURVA) and Daratumumab (DARA (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Protocol Number
639359MDS3001

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (FLAURA1)

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5160C00007

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
AV001

To Learn More Call
201-510-0910

An Open-label Bosutinib Treatment Extension Study for Subjects with Chronic Myeloid Leukemia (CML) who have Previously Participated in Bostutinib Studies B1871006 or B1871008

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
B1871040-1134

To Learn More Call
201-510-0910

A Phase 1, Dose-Escalation/ Dose-Expansion Study Evaluating the Safety, pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvuluman (DURVA) and Daratumumab (DARA (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Protocol Number
639359MDS3001

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (FLAURA1)

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5160C00007

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
AV001

To Learn More Call
201-510-0910

An Open-label Bosutinib Treatment Extension Study for Subjects with Chronic Myeloid Leukemia (CML) who have Previously Participated in Bostutinib Studies B1871006 or B1871008

Type of Cancer
Leukemia

Site
Bethesda

Protocol Number
B1871040-1134

To Learn More Call
201-510-0910

A Phase 1, Dose-Escalation/ Dose-Expansion Study Evaluating the Safety, pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvuluman (DURVA) and Daratumumab (DARA (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Protocol Number
639359MDS3001

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (FLAURA1)

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5160C00007